Clinical & translational oncology

• 

  Año 2026, Vol. 28, Número 7

  • REVIEW ARTICLE

    • Adoptive cell therapies in thoracic malignancies: a comprehensive review

      Yago Garitaonaindia, Marta Martínez Cutillas, María Uribarren, Isabel Redondo, Virginia Calvo de Juan, Roberto Serna Blasco, Mariano Provencio Pulla

      • Resumen

      págs. 2435-2448

      

    • The evolution of cellular-based immunotherapy in the treatment of gastric cancer: an overview of clinical trials

      Lang Wu, Jasur Rizaev, Khaled Fahmi Fawy, Mustafa Jawad Kadham, Nabieva Dildora, Shakhlokhon Kurbanova, Zamira Atamuratova, Asilbek Dauletbaev, Natrayan Lakshmaiya, Raed Fanoukh Aboqader Al Aouadi

      • Resumen

      págs. 2449-2467

      

    • Research progress in diagnosis and treatment of pancreatic cancer with mismatch repair and microsatellite instability

      Hang Yin, Yong Liu, Jiatong Chen, Zhuang Li, Yue Pan, Feng Zhu

      • Resumen

      págs. 2468-2480

      

    • Exploring correlations of CA19-9 with serum enzyme ratios: can layered biomarker strategies enhance prognostic accuracy in pancreatic cancer?

      Akanksha Saini, Manik Mehta, Dinesh Kumar Mehta, Kishor Kumar Roy, Rina Das

      • Resumen

      págs. 2481-2497

      

    • Neutrophil extracellular traps (NETosis) in gynecologic cancers: from pathogenesis to therapeutic opportunities: a narrative review

      Naina Kumar

      • Resumen

      págs. 2498-2517

      

    • Mechanistic insights into HAGLROS-mediated therapy resistance in ovarian cancer

      Mohadeseh Sheykhi-Sabzehpoush, Hamed Abedzeydi, Maryam Khombi Shooshtari, Maryam Cheraghzadeh, Farideh Moramezi, Ali Khavanin, Maryam Farzaneh

      • Resumen

      págs. 2518-2522

      

    • CTLA-4: a promising immunosuppressive immune checkpoint in prostate cancer therapy

      Nada Khairi Younis, Ali Fawzi Al Hussainy, S. Renuka Jyothi, Priya Priyadarshini Nayak, J. Bethanney Janney, Gurjant Singh, Djamila Polatova, Hayder Naji Sameer, Rasim M. Salih, Mohaned Adil

      • Resumen

      págs. 2523-2549

      

    • Synergistic mechanisms and clinical translation of regorafenib combination therapies

      Shaokui Liang, Dayuan Zheng, Tong Chu, Dongfan Yang, Kuanyun Zhang, Lu Yang, Yanchao Yang, Wenzhe Ma

      • Resumen

      págs. 2550-2563

      

    • Splicing-driven post-translational dysregulation: a new frontier for precision cancer medicine and immunotherapy

      Sael Alatawi

      • Resumen

      págs. 2564-2579

      

    • Antitumoral and cardioprotective roles of statins: underlying types, mechanisms, current evidence, and emerging perspectives

      Ibrahim El Sayed

      • Resumen

      págs. 2580-2592

      

  • SPECIAL ARTICLE

    • Consensus document between oncology and primary care for the follow-up of cancer survivors

      María del Rosario Vidal Tocino, Rafael Manuel Mico Pérez, María Hernández Miguel, Yolanda Ginés, Raúl Hernanz, Lourdes Martínez-Berganza Asensio, Ruth Vera García, Fátima Santolaya Sardinero, Elena Brozos Vázquez, Jacinto Bátiz Cantera, Cruz Bartolomé Moreno

      • Resumen

      págs. 2593-2602

      

    • Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology

      Margarita Majem, Kevin Molina Mata, Ander Mayor Ibarguren, Marta Zafra Poves, Celia Requena, Francisco Aparisi Aparisi, Cristina Carrera, Ana Blasco Cordellat, Azael Freites-Martínez, Onofre Sanmartín Jiménez

      • Resumen

      págs. 2603-2624

      

  • RESEARCH ARTICLE

    • Impact of vitamin D deficiency and inflammatory biomarkers on pathological response to neoadjuvant chemotherapy in breast cancer

      Kadriye Başkurt, Galip Can Uyar, Enes Yeşilbaş, Orhun Akdoğan, Tuba Ugur Tuzcu, Omur Berna Cakmak Oksuzoglu, Kadriye Bir Yücel, Osman Sütcüoğlu

      • Resumen

      págs. 2625-2637

      

    • The miRNA-4330/ABCG2 axis overcomes drug resistance and cancer progression in both ER-positive and ER-negative resistant breast cancer cells

      Shaymaa M. M. Yahya, Sohair M. Salem, Heba K. Nabih, Shimaa Ibrahim Abdelmenym Mohamed, Ghada H. Elsayed

      • Resumen

      págs. 2638-2653

      

    • “Beyond HER2 overexpression: somatic alterations in HER2 and PI3K genes in HER2-high and HER2-low/TNBC breast cancer

      Tamanna Thakur, Siddhant Khare, Santosh Irriniki, Ishita Laroiya, Rajender Kumar, Shalmoli Bhattacharyya, Amanjit Bal

      • Resumen

      págs. 2654-2664

      

    • Combined positive score status in metastatic triple-negative breast cancer patients treated with sacituzumab govitecan: associated clinical characteristics and testing patterns in a Central European cohort

      Karolina Winsko Szczęsnowicz, Małgorzata Pieniążek, Anna Polakiewicz Gilowska, Marcin Kubeczko, Miloš Holánek, Miroslava Malejčíková, Renáta Soumarová, Hana Študentová, Aleksandra Konieczna, Agnieszka Młodzińska, Justyna Żubrowska, Maja Lisik Habib, Anika Pękala, Daniel Krejčí, Jan Šustr, Iveta Kolářová, Iwona Danielewicz, Magdalena Szymanik Resko, Tomasz Ciszewski, Lenka Rusinová, Bogumiła Czartoryska Arłukowicz, Aleksandra Łacko, Michał Jarząb, Zuzana Bielčiková, Mirosława Püsküllüoğlu

      • Resumen

      págs. 2665-2674

      

    • Clinical efficacy and safety of Cadonilimab immunotherapy in recurrent or metastatic gynecological malignancies: a retrospective study

      Lulu Lou, Jiahong Jiang

      • Resumen

      págs. 2675-2681

      

    • Futility in patients with peritoneal carcinomatosis of ovarian origin undergoing or who underwent interval cytoreductive surgery: a multicenter retrospective observational study

      Silvia Carbonell Morote, Álvaro Arjona Sánchez, Pedro Antonio Cascales Campos, Alida Gonzalez Gil, G. Gómez Dueñas, Elena Gil, Ibán Caravaca García, Verónica Aranaz Ostáriz, Francisco Javier Lacueva Gómez, José Manuel Ramia Ángel

      • Resumen

      págs. 2682-2689

      

    • Evaluation of ICAM and VCAM as biomarkers in serum and bronchoscopic lavage samples of lung cancer patients

      Burcu Nur Gülbahar, Alperen Aksakal, Buğra Kerget, Nurinnisa Öztürk, Ömer Araz, Elif Yilmazel Ucar, Leyla Sağlam

      • Resumen

      págs. 2690-2700

      

    • Survival of lung cancer patients with central nervous system metastases: from clinical trials to mouse models

      Hainan Yang, Chengji Wang, Hui Ye, Tao Lin, Weifang Yuan, Changguo Shan, Qingjun Hu, Xin Jin, Da Liu, Lei Wen, Ming Lei

      • Resumen

      págs. 2701-2710

      

    • Genetic evidence for POR-mediated ferroptosis in lung cancer prevention: a causal role of granulocyte modulation

      Lujie Qian, Linyu Wu, Xinjing Lou, Ning Kong, Ting Wu, Hongjie Hu, Maosheng Xu, Chen Gao

      • Resumen

      págs. 2711-2720

      

    • Impact of image-guided radiation therapy with intraprostatic seeds on long-term toxicity in prostate cancer patients undergoing risk-adapted intensification therapy

      Almudena Zapatero Laborda, Pablo Castro Tejero, Carmen Martín de Vidales, Maria Roch, Nuria Montes, Alfonso Cruz Conde, Alexandra Stoica, Carmen Villalba, Isabel Nafría, Feliciano García-Vicente

      • Resumen

      págs. 2721-2730

      

    • Risk-adapted management in stage I testicular germ-cell tumors: long-term outcomes from a single-center cohort (1994–2023)

      Patricia Capdevila, Cristobal Carrasco, Saturnino Luján Marco, David Ramos Soler, Jorge Aparicio Urtasun

      • Resumen

      págs. 2731-2738

      

    • Peritoneal metastasis histological grade independently predicts outcome in pseudomyxoma peritonei treated with curative surgery

      Awen Hasan, Bipasha Chakrabarty, Christopher Kearsey, Raghavendar Nagaraju, Malcolm Wilson, Andrew Renehan, Rebecca Fish, Paul Sutton, Jonathan Wild, Chelliah Selvasekar, Hamish Clouston, Jorge Barriuso, Sarah Theresa O'Dwyer, Omer Aziz

      • Resumen

      págs. 2739-2748

      

    • Malignant cell-secreted chemokines drive colorectal cancer progression through endothelial cell activation

      Xiaohan Guo, Yichun Huang, Yuxuan Sun, Wenbing Pu, Peng Miao, Qian Pan, Na Xie

      • Resumen

      págs. 2749-2765

      

    • IRS2 as a driver and therapeutic target in brain metastases from colorectal cancer: a systematic review of mechanistic and translational evidence

      Siddharth Shah, Brandon Lucke Wold

      • Resumen

      págs. 2766-2777

      

    • Correlation analysis of gut microbiota and metabolites in gastric cancer patients in plateau areas based on multi-omics technologies

      Shengdong Li, Yanqing Ma, Zilong Zhang, Linghong Zhu

      • Resumen

      págs. 2778-2791

      

    • Proteomic profiling identifies an oncogene ITGA2 and its downstream targets in gastric cancer

      Michelle Xin Liu, Kent-Man Chu

      • Resumen

      págs. 2792-2802

      

    • CCDC137 affects sorafenib resistance in hepatocellular carcinoma cells by activating the AKT/mTOR signaling pathway

      Hanchuan Tao, Yu Wang, Fang Wang, Xingchi Hu, Cheng Wang

      • Resumen

      págs. 2803-2814

      

    • Single-cell and spatial transcriptomics reveal mTOR-driven cellular fate of spindle cells and immune evasion in classic Kaposi’s sarcoma

      Ting Su, Yongkai Yu, Xuechen Cao, Yidan Wang, Zhonglan Su, Guoxin Song, Lu Sun, Yue Chen, Yan Lu

      • Resumen

      págs. 2815-2831